Screening Approaches for Reducing Attrition Due to Drug-induced Liver Injury (DILI) Early in Drug Discovery

, , , , , , ,

 

 

Screening Approaches for Reducing Attrition Due to Drug-induced Liver Injury (DILI) Early in Drug Discovery

Date: Wednesday, June 10, 2020
Time: 9:00am PDT / 12:00pm EDT
Duration: 1 hour
Register today

In this webinar, we will discuss a set of in vitro assays that tackle the challenges of in vitro hepatotoxicity assessment. We will discuss the utilization of a portfolio of cell-based in vitro assays, including assays that assess mitochondrial dysfunction, toxic effect by reactive metabolites, induction of reactive oxygen species (ROS), and cholestasis. We will also discuss the major cell types that are used in in vitro hepatotoxicity screening.

Sponsored by:

About Us: Xconomy is the authoritative voice for the life sciences, focusing on funding, partnerships, and technologies supporting research and development of novel therapeutics. Our independent editorial team delivers the latest news and analysis on the financials and innovations driving startups as they move from discovery and development toward commercialization. And our business-to-business events, award shows, webinars, podcasts, and whitepapers keep entrepreneurs, investors, and scientists relevant and informed – while facilitating deep, valuable connections and collaborations across the ecosystem.